Tech Transfer Central
Tech Transfer eNews

Tech Transfer E-News provides a weekly round-up of current news and information in the world of tech transfer, delivered every Wednesday (sign up here). It is published by Technology Transfer Tactics newsletter, which is available as a monthly subscription. For more information or to order a subscription click here, or for a sample issue, click here.

U of Cincinnati start-up develops AI tool for diagnosing coronary artery disease risk in women

A University of Cincinnati (UC) spinout aims to commercialize an AI technology that could diagnose the risk of coronary artery disease in women during routine mammograms.

Genexia has developed explainable AI — or a system of AI that can provide transparent and human-friendly explanations for its decisions and actions — to improve the way coronary artery disease risk is diagnosed in women and marrying the technology to routine mammograms, thus capturing diagnoses much more widely than currently. According to the start-up, the guidelines used for coronary artery disease risk today come from studies in the 1990s that were done almost exclusively on men.

“Our explainable AI to diagnose coronary artery disease risk will immediately help a lot of women live long, fulfilling lives,” says Dino Martis, CEO of Genexia. “Because this will be done as part of an annual or biennial mammogram where no additional images are needed and will fit seamlessly within existing workflows, the individual receives two preventative diagnoses from a mammogram at no [additional] cost, resulting in true health equity and democratization.”

UC researchers Anoop Sathyan and Kelly Cohen initially developed the technology and enrolled in UC’s Venture Lab to launch Genexia with Martis, one of the lab’s entrepreneurs-in-residence.

“We don’t have the training and understanding of what it takes to start up a business, and we don’t have the experience,” says Cohen. “Without the process we went through with the Venture Lab and Dino’s expertise in founding and scaling health care companies, we wouldn’t have been able to reach this stage.”

Genexia is currently fundraising to launch a clinical trial, after which it will seek FDA approval for its diagnostic technology. According to the start-up, it could be commercially available as early as 2027.

Source: UC News

IP Protection and Generative AI Technologies is a distance learning program providing a detailed look at the current legal landscape for Generative AI tools and expert legal insight into the future as new cases and regulations emerge.

Posted under: Tech Transfer e-News